Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Safety and Tolerability Study of Dapivirine (TMC120) Vaginal Microbicide Gel

This study has been completed.
Information provided by:
International Partnership for Microbicides, Inc. Identifier:
First received: March 15, 2006
Last updated: July 28, 2006
Last verified: July 2006
Approximately 112 HIV-negative women, aged 18 to 50, will be enrolled in this multicenter study at four sites. Volunteers will be randomized to dapivirine (TMC120) vaginal gel or matching placebo gel. The volunteers will receive investigational product for a total of 42 days. Volunteers will be monitored on days 7, 28 and 42 for safety, tolerability and compliance.

Condition Intervention Phase
HIV Infections
Drug: dapivirine (TMC120) vaginal gel
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Prevention
Official Title: A Phase I/II Double-Blind, Randomized Study of the Safety, Tolerability and Systemic Absorption of TMC120 Vaginal Microbicide Gel and Matching Placebo in Healthy HIV-Negative Women.

Resource links provided by NLM:

Further study details as provided by International Partnership for Microbicides, Inc.:

Primary Outcome Measures:
  • Local and systemic safety and tolerability.

Estimated Enrollment: 112
Study Start Date: October 2005
Estimated Study Completion Date: July 2006

Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • HIV-negative
  • Willing to participate and sign an informed consent
  • Willing to be tested for HIV, use an experimental vaginal gel, and to be randomized to a study group that includes the possibility of being assigned to a placebo group.
  • Willing to use two forms of contraception during the study.
  • Willing to undergo pelvic examinations with colposcopy and photographic documentation according to the protocol throughout the study.
  • Have a regular menstrual cycle defined as having a minimum of 21 days and a maximum of 36 days between menses.
  • Willing to abstain from using any vaginal product (other than the study product or placebo).
  • Willing to be sexually abstinent from randomization until completion of Day 7 evaluations.

Exclusion Criteria:

  • Currently pregnant or breast-feeding.
  • Clinically detectable genital abnormality on the vulva, vaginal walls or cervix.
  • Laboratory confirmed gonorrhea, chlamydia, trichomonas, syphilis, or vaginal candidiasis or clinically diagnosed genital ulcer disease or active HSV-2 lesions.
  • Breakthrough bleeding or gynecologic surgery within 60 days prior to randomization.
  • Symptomatic bacterial vaginosis and unwilling to undergo treatment.
  • Women who require treatment for tuberculosis (TB) within 21 days prior to randomization.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00303576

Projet Ubuzima
Kigali, Rwanda
South Africa
Reproductive Health Research Unit - Sheshisani IPM Clinic
Yeoville, Johannesburg, South Africa
Bloemfontein, South Africa
Kilimanjaro Reproductive Health Program
Moshi, Tanzania
Sponsors and Collaborators
International Partnership for Microbicides, Inc.
Study Director: Zeda Rosenberg, ScD IPM
  More Information Identifier: NCT00303576     History of Changes
Other Study ID Numbers: IPM003
Study First Received: March 15, 2006
Last Updated: July 28, 2006

Keywords provided by International Partnership for Microbicides, Inc.:
HIV Seronegativity

Additional relevant MeSH terms:
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Anti-Infective Agents processed this record on April 21, 2017